查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1190481

C 反应蛋白检测市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

C-Reactive Protein Testing Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

C 反应蛋白 (CRP) 检测市场预计在预测期内（2022 年至 2027 年）以 1.8% 的复合年增长率增长。

COVID-19 正在以前所未有的方式影响医疗保健和诊断行业。 例如，根据 2020 年 5 月发表在《临床微生物学和抗菌药物年鑑》上的一项题为“血浆 CRP 水平与 COVID-19 的严重程度正相关”的研究，血浆 CRP 水平与 COVID-19 肺炎的严重程度相关。被揭露相关。 这一发现可能有助于区分轻度 COVID-19 肺炎患者和中重度 COVID-19 肺炎患者。 这是严重疾病的早期预警信号，可以让医生更好地对患者进行分层，以便将其转移到重症监护病房。 CRP 检测对 COVID-19 感染患者分层的重要性将导致对 CRP 检测的需求增加，从而影响大流行期间的市场增长。

推动 C 反应蛋白检测市场增长的主要因素是炎症性疾病、糖尿病、癌症患病率上升、全球女性子宫内膜异位症发病率上升，其中包括对技术进步的资金投入增加以及点-护理设备。

根据美国疾病控制与预防中心发布并于 2022 年 7 月更新的数据，美国约有 2010 万 20 岁及以上的成年人患有冠状动脉疾病。. 另据报导，美国每年约有 805,000 人心脏病发作。 心血管疾病患病率上升将导致更多地采用 CRP 检测来识别与心血管疾病相关的风险，从而推动市场增长。

此外，越来越多的床旁 CRP 检测产品发布有望促进 CRP 检测市场的增长。 例如，2020 年 5 月，ProciseDx 为 Procise CRP 测试提交了 510k。 该测试是利用 ProciseDx 的 FRET（荧光共振能量转移）护理点设备进行的，这是一种在胃肠道治疗中广泛使用的炎症标记物。

因此，预计在预测期内，心血管疾病患病率上升和床旁 CRP 检测产品发布数量增加等因素将推动该市场的增长。 另一方面，缺乏公众意识和替代疗法的可用性预计会阻碍市场的增长。

主要市场趋势

在预测期内，□联免疫吸附测定 (ELISA) 部分预计将占据很大的市场份额

□联免疫吸附测定 (ELISA) 部分预计将在 C 反应蛋白检测市场的测定类型中占据很大份额。 癌症患病率上升、COVID-19等传染病数量增加、ELISA 测试商业化合作伙伴关係激增以及产品发布激增等因素将在预测期内推动该细分市场的增长。

根据 Globocan 2020，2020 年全球将有 1930 万癌症患者和 1000 万癌症死亡病例。 由于 ELISA 测试是早期检测癌症的有用方法，因此有望在全球范围内引入用于癌症检测并引领该领域的发展。

此外，提供相同测试的设施的建立也有望促进市场的增长。 例如，2021 年 6 月，Trivitron Healthcare 推出了 COVID-19 诊断移动实验室，以促进印度城市、农村和偏远地区的 COVID-19 诊断。 这个本土实验室提供诸如 D-二聚体、CRP 和 IL-6 等炎症标誌物的 CLIA/Elisa 测试、RT-PCR 测试、快速抗原测试、CLIA/Elisa 抗体测试 IgG 和 IgM 等测试。

因此，预计在预测期内，产品发布的增加、研究合作的增加以及癌症患病率的上升将推动该细分市场的增长。

北美将占据很大的市场份额，预计在预测期内也会如此

北美以较大的收入份额占据市场主导地位。 促成这一细分市场占据主导地位的因素包括心血管疾病患病率上升、产品发布增加、现有参与者的存在、技术进步和完善的医疗基础设施。

此外，根据罗斯福大学药学院 2020 年 9 月在 Frontiers in Immunology 上发表的题为“How C-Reactive Protein Structural Isoforms With Distinctive Bioactivities Affect Disease Progression”的研究，CRP 作为原型急性期反应物几十年来，c-反应蛋白（c-reactive protein）的测试功能生物活性一直没有明确定义，导致诊断学家使用 CRP 血液水平作为各种状况和疾病持续炎症的快速指标。据说 希望此类研究将导致进一步采用 CRP 检测来诊断体内炎症。

此外，2020 年 10 月，Nova Biomedical 为其 Allegro 毛细血管血液学分析仪推出了 CRP（C 反应蛋白）测试，用于初级保健环境中的即时 (POC) 测试。。 Allegro 及其配套仪表 StatStrip 提供 11 项临床相关测试，以帮助临床医生做出治疗决策和改变。 美国越来越多的 CRP 测试产品推出预计将推动这些测试的采用，并推动美国市场的增长。

因此，心血管疾病患病率上升和产品发布增加等因素预计将推动北美市场的增长。

竞争格局

C 反应蛋白检测市场分散且竞争激烈。 主要参与者之间建立战略伙伴关係以扩大产品组合、扩大研发、分销和行政设施以增强市场竞争力等因素预计将推动市场增长。 该市场的公司包括雅培实验室、丹纳赫公司（贝克曼库尔特公司）、F. Hoffmann-La Roche AG、默克公司、Quest Diagnostics、Thermo Fisher Scientific Inc. 等公司。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 炎症性疾病的患病率上升
    • 全球女性子宫内膜异位症患病率上升
    • 增加对诊断技术进步的资助
    • 越来越多地采用床旁设备
  • 市场製约因素
    • 社会意识低
    • 更准确的替代疗法的可用性
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 按检测类型
    • □联免疫吸附试验 (ELISA)
    • 化学发光免疫分析 (CLIA)
    • 免疫比浊法
    • 其他检测类型
  • 通过申请
    • 糖尿病
    • 类风湿性关节炎
    • 心血管疾病
    • 炎症性肠病
    • 癌症
    • 其他用途
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Zoetis（Abaxis Inc.）
    • Abbott Laboratories
    • Danaher Corporation（Beckman Coulter Inc.）
    • F. Hoffmann-La Roche AG
    • Laboratory Corporation of America Holdings
    • Merck KGaA
    • Quest Diagnostics
    • Randox Laboratories Ltd
    • Siemens Healthineers
    • Thermo Fisher Scientific Inc.
    • Getein Biotech, Inc.
    • HORIBA, Ltd
    • Boditech Med Inc.
    • Aidian

第7章 市场机会今后动向

简介目录
Product Code: 60431

The C-reactive protein (CRP) testing market is projected to register a CAGR of 1.8% during the forecast period (2022-2027).

COVID-19 has had an unprecedented effect on the healthcare and diagnostic industry. For instance, according to the study published in Annals of Clinical Microbiology and Antimicrobials, titled "Plasma CRP level is positively associated with the severity of COVID-19" in May 2020, plasma CRP levels were found to be linked to the severity of COVID-19 pneumonia. The findings could help distinguish mild COVID-19 pneumonia patients from those with moderate to severe COVID-19 pneumonia. This could serve as an early warning sign of serious disease, allowing doctors to better stratify patients for transfer to an intensive care unit. The importance of CRP testing in the COVID-19 infection for the stratification of patients will lead to increased demand for CRP testing, thereby impacting the market growth during the pandemic.

The major factors propelling the growth of the C-reactive protein testing market include the rise in prevalence of inflammatory disorders, diabetes, and cancers; the increasing global incidence of endometriosis in women; the rise in funding for technological advancement in diagnostics; and the rise in adoption of point-of-care devices.

According to the data published by the Center for Disease Control and Prevention and updated in July 2022, there are about 20.1 million adults aged 20 and older in United States who have coronary artery disease. It also reported that in United States, every year, about 805,000 people have a heart attack. The rising prevalence of cardiovascular diseases will lead to increased adoption of CRP testing to identify the risk associated with cardiovascular disease, thereby driving the market growth.

Furthermore, the rise in product launches of point-of-care CRP tests is expected to contribute to the growth of the CRP testing market. For instance, in May 2020, ProciseDx filed a 510k for the Procise CRP test. The test is performed utilizing ProciseDx's FRET (Fluorescent Resonance Energy Transfer) Point of Care equipment, which is an inflammatory marker extensively used in gastrointestinal therapy.

Therefore, the rising prevalence of cardiovascular disease and rising product launches for point-of-care CRP testing, among others, are expected to drive the growth of this market over the forecast period. On the other hand, lack of public awareness and the availability of alternative treatments are the factors that are expected to hinder the market's growth.

Key Market Trends

Enzyme-linked Immunosorbent Assay (ELISA) Segment is Expected to Hold a Significant Share in the Market Over the Forecast Period

The Enzyme-linked Immunosorbent Assay (ELISA) segment is expected to hold a significant share in the C-reactive protein testing market by assay type. Factors such as the rise in the prevalence of cancers; the growth in infections such as COVID-19; the surge in partnerships for the commercialization of ELISA tests; and an upsurge in product launches, among others, are expected to drive the growth of this segment during the forecast period.

According to Globocan 2020, the global cancer burden has risen to 19.3 million cases and 10 million cancer deaths in 2020. As the ELISA test can be a useful technique for detecting cancer early on, there will be increased adoption of these tests for the detection of cancer across the world, thereby driving the segment's growth.

Furthermore, the establishment of the facilities providing the test is also expected to boost the growth of the market. For instance, in June 2021, Trivitron Healthcare launched the mobile laboratory for COVID-19 diagnostics to facilitate COVID-19 diagnostics in urban, rural, and far-flung geographies across India. The indigenous lab provides tests for CLIA/Elisa tests for inflammatory markers like D-Dimer, CRP & IL-6, RT-PCR tests, rapid antigen tests, CLIA/Elisa Antibodies Tests IgG and IgM, and others.

Therefore, rising product launches, a rise in collaborations, and a rise in the prevalence of cancer are expected to drive the growth of this segment over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period

North America dominated the market with a large revenue share. The factors that are likely to be responsible for the dominance of this segment are the rise in the prevalence of cardiovascular diseases, rising product launches, the presence of established players, technological advancements, and well-established healthcare infrastructure.

In addition, according to the study published in Frontiers in Immunology, titled "How C-Reactive Protein Structural Isoforms With Distinctive Bioactivities Affect Disease Progression" in September 2020 by the Roosevelt University College of Pharmacy, United States, because of the c-reactive protein (CRP) test functional bioactivity as the prototypic acute phase reactant has eluded clear definition for decades, diagnosticians of various conditions and diseases use CRP blood levels as a simple index for ongoing inflammation. Such studies will lead to further adoption of CRP testing for the diagnosis of inflammation in the body.

Furthermore, in October 2020, Nova Biomedical launched the Allegro C-reactive protein (CRP) test for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. The Allegro and its StatStrip companion meter give 11 clinically necessary tests to assist clinicians in making therapeutic decisions and changes. The increasing product launches for CRP testing in United States will lead to increased adoption of these tests, which is thereby expected to drive the growth of this market in United States.

Therefore, the rising prevalence of cardiovascular diseases and rising product launches, among others, are the factors expected to drive the growth of this market in North America.

Competitive Landscape

The C-reactive Protein testing market is fragmented and competitive. Factors such as strategic partnerships between key market players to expand their product portfolios; expansion in research and development; distribution; and management facilities to gain a competitive edge in the market are expected to drive the market's growth. Some of the companies in this market include Abbott Laboratories, Danaher Corporation (Beckman Coulter Inc.), F. Hoffmann-La Roche AG, Merck KGaA, Quest Diagnostics, and Thermo Fisher Scientific Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Prevalence of Inflammatory Disorders
    • 4.2.2 Increasing Global Incidence of Endometriosis in Women
    • 4.2.3 Rise in Funding toward the Technological Advancement in Diagnostics
    • 4.2.4 Rise in the Adoption of Point-of-care Devices
  • 4.3 Market Restraints
    • 4.3.1 Lack of Public Awareness
    • 4.3.2 Availability of Alternative Treatments with Higher Accuracies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Assay Type
    • 5.1.1 Enzyme-linked Immunosorbent Assay (ELISA)
    • 5.1.2 Chemiluminescence Immunoassay (CLIA)
    • 5.1.3 Immunoturbidimetric Assay
    • 5.1.4 Other Assay Types
  • 5.2 By Application
    • 5.2.1 Diabetes
    • 5.2.2 Rheumatoid Arthritis
    • 5.2.3 Cardiovascular Disease
    • 5.2.4 Inflammatory Bowel Disease
    • 5.2.5 Cancer
    • 5.2.6 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Zoetis (Abaxis Inc.)
    • 6.1.2 Abbott Laboratories
    • 6.1.3 Danaher Corporation (Beckman Coulter Inc.)
    • 6.1.4 F. Hoffmann-La Roche AG
    • 6.1.5 Laboratory Corporation of America Holdings
    • 6.1.6 Merck KGaA
    • 6.1.7 Quest Diagnostics
    • 6.1.8 Randox Laboratories Ltd
    • 6.1.9 Siemens Healthineers
    • 6.1.10 Thermo Fisher Scientific Inc.
    • 6.1.11 Getein Biotech, Inc.
    • 6.1.12 HORIBA, Ltd
    • 6.1.13 Boditech Med Inc.
    • 6.1.14 Aidian

7 MARKET OPPORTUNITIES AND FUTURE TRENDS